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Abstract: Cytokines are mediators of inflammation induced in the course of Clostridioides difficile
infection (CDI). High Mobility Group Box 1 (HMGB1) is a cytokine playing an important role in the
pathogenesis of numerous inflammatory and autoimmune diseases. The aim of the study was to assess
the HMGB1 gene expression in the course of CDI. We have performed a prospective case-control study-
including 55 adult patients, among them 27 with CDI, who were hospitalized from October 2018 to
February 2020 and 28 healthy volunteers. We assessed: a complete blood count with differential
leukocyte count, blood creatinine, albumin, and C-reactive protein (CRP) levels. Then, the expression
of the HMGB1 gene was evaluated using quantitative Real-Time PCR. Patients with CDI were found
to have a significant increase in white blood cells (WBC), neutrophil count, and CRP levels, they also
exhibited decreased levels of albumin compared with controls. The HMGB1 gene expression was
significantly lower among patients with CDI compared with the control group and significantly,
inversely correlated with CRP level in blood. In conclusion, we have observed a decreased expression
of the HMGB1 gene in peripheral blood of patients with mild or moderate CDI, which hypothetically
could reflect their diminished capability to fight the pathogen.
Keywords: genetic; infection; inflammation; pathogenesis
1. Introduction
Clostridioides difficile infection (CDI) is caused by anaerobic bacilli of the species Clostridioides
difficile (C. difficile), formerly known as Clostridium difficile, widespread in the human environment [1].
In the last two decades, the incidence and severity of CDI have been growing worldwide, reinforcing it
as one of the most eminent nosocomial infections of modern healthcare. Infection occurs through
the fecal-oral route, the most important risk factors for the development of the disease are the use of
antibiotics, hospitalization, and older age. The pathogen itself is not directly invasive- its virulence
factors are enzymes it produces, such as collagenase, hyaluronidase, chondroitin sulfatase, and toxins,
which destroy the intestinal epithelium cytoskeleton and stimulate adhesion of neutrophils to the
intestinal wall, causing inflammation and loss of both the integrity and functionality of the intestinal
mucosa. Cytokines: interleukin 8 (IL-8), interleukin 1β (IL-1β), interleukin 6 (IL-6), tumor necrosis
factor α (TNFα), interferon γ (IFN γ), and leukotriene B4 also play an important part in CDI
pathogenesis [2,3]. The clinical picture of CDI is diverse and ranges from asymptomatic carrier status,
Microorganisms 2020, 8, 1217; doi:10.3390/microorganisms8081217 www.mdpi.com/journal/microorganisms
Microorganisms 2020, 8, 1217 2 of 9
through various degrees of diarrhea, to most severe colitis often leading to death. The prevalence of
C. difficile colonization during hospitalization correlates to the length of stay, and in a few weeks can
reach even 50% of patients [3–6]. However only some become symptomatic [7], the reason for this
remains unknown. Moreover, the severity of CDI may vary even between people similar in age and
co-morbidities [8]. Genetic diversity, reflected in differences in immune system functionality of the
patients may, at least partially, be a factor in CDI risk and/or variance of its course.
High Mobility Group Box 1 (HMGB1) is a cytokine located in the cell nucleus. There, it plays a
vital part in maintaining chromosome structure and DNA damage prevention [9]. During the cellular
stress response, it is released into the cytosol, and subsequently extracellularly, where it mediates
the inflammatory, defense response and other cellular processes [9–11]. Efron et al. assessed genetic
profiles of leukocytes in trauma patients, demonstrating an increased expression of the HMGB1 gene
in the subgroup of patients who developed CDI [12].
Therefore, the aim of our study was to prospectively assess HMGB1 gene expression in the course
of CDI.
2. Materials and Methods
2.1. Study Population
We prospectively studied 55 patients. The study group included 27 patients with mild or moderate
CDI hospitalized at the Department of Infectious and Tropical Diseases, University Hospital in Krakow,
Poland, from October 2018 to February 2020, and 28 healthy volunteers. All individuals were of
Caucasian race. Infection was confirmed by detection of C. difficile antigen and toxins in feces using the
TOX A/B Wampole Quick Check Complete test kit (TechLab Inc., Blacksburg, VA, USA). When the
test came back positive for the antigen but negative for the toxin, the test for the C. difficile toxin was
repeated with the C. difficile Toxin ELISA A/B II test kit (TechLab Inc., Blacksburg, VA, USA). A CDI case
was defined as a patient with symptoms of CDI and positive laboratory test(s) according to the European
Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines [13]. Exclusion criteria
included the presence of any CDI episode in control group, and the presence of acute or chronic
inflammatory diseases in both groups. Patients with any infection in the control group, and any other
infection than CDI in the CDI group were also excluded. All subjects had given their informed consent
for inclusion before they participated in the study. The study was conducted in accordance with the
Declaration of Helsinki (as revised in Brazil 2013). The study protocol was approved by the Ethics
Committee of Jagiellonian University, ID number 1072.6120.211.2017.
2.2. Blood Tests
Blood samples were collected in the morning, between 7.00 and 8.00 a.m. after an overnight fast.
They were taken at the beginning of infection, no later than 48 h after CDI diagnosis. We assessed
the following: complete blood count with differential leukocyte count, serum creatinine, albumin,
and C-reactive protein (CRP) levels. All tests were performed according to generally accepted
standard procedures.
2.3. Gene Expression Assay
Whole blood was collected into 5 mL EDTA-treated tubes. Buffy coat fractions were prepared
by centrifugation of the collection tubes at 1500× g for 15 min at room temperature. Next, the buffy
coats were mixed in equal volume of DNA/RNA Shield (2× concentrate) (Zymo Research, Irvine,
CA, USA) and samples were stored in −80 ◦C. RNA was isolated from 500 µL of a sample by
using the Quick-RNA™ Miniprep Plus Kit (Zymo Research, Irvine, CA, USA), following the
manufacturer’s instructions. One hundred and eighty nanograms of extracted RNA per sample were
reverse-transcribed to cDNA by a High Capacity RNA-to-cDNA Kit (Applied Biosystems, Waltham,
MA, USA). Quantitative RT–PCR was performed in triplicate with 2 µL of cDNA, 1× TaqMan®
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Fast Advanced Master Mix and 1× TaqMan® Gene Expression assay HMGB1 (ID: Hs01923466_g1),
glyceraldehyde-3-phosphate dehydrogenase GAPDH (ID: Hs02786624_g1), and actin beta ACTB (ID:
Hs01060665_g1) (Applied Biosystems, Foster City, CA, USA) in a final reaction volume of 20 µL.
Samples were amplified by the CFX96 Touch Real-Time PCR System (Bio-Rad, Pleasanton CA, USA)
under the following thermal profile: initial incubation at 95 ◦C for 2 min, 40 cycles of denaturation
at 95 ◦C for 1 s followed by annealing and extension at 60 ◦C for 20 s. Mean quantitation cycle (Cq)
values of HMGB1 were normalized to the geometric mean of GAPDH and ACTB, which were selected
as stable, housekeeping genes [14–16]. Data were expressed for each sample as ∆Cq, which is the
difference between the Cq HMGB1 value and the geometric mean of Cq values of GAPDH and ACTB
for a particular sample.
2.4. Statistical Analysis
All data are presented as medians with lower (Q25), and upper (Q75) quartiles. Normal distribution
of variables was analyzed using the Shapiro-Wilk test. Differences between study groups were
determined using the Mann-Whitney test if normality was not observed. Correlation between selected
variables was evaluated using Spearman’s rank correlation. Calculations were performed using
StatSoft, Inc. (2011), STATISTICA, version 13.3 statistical software licensed for Jagiellonian University,
and statistical significance was defined as p ≤ 0.05.
3. Results
The study group included 27 patients with mild or moderate CDI hospitalized at the Department of
Infectious and Tropical Diseases, University Hospital, in Krakow, median age of 71 years, and 28 healthy
volunteers median age of 69 years. Patients with CDI were found to have a significant increase in
white blood cells (WBC), neutrophil count, and CRP levels, they also exhibited decreased levels of
albumin compared with controls. HMGB1 gene expression was significantly lower in the CDI group
compared with the control group (Table 1).
Table 1. Results of the assessed parameters in the study groups.
Parameter
CDI Group Control Group P
n Median (Q25–Q75) n Median (Q25–Q75)
Age (years) 27 71 (67–84) 28 69 (65–72) 0.17
WBC (×103/µL) 27 8.9 (6.8–12.3) 28 5.8 (5.1–6.8) <0.001
neutrophils (×103/µL) 26 6.5 (4.4–9.7) 28 2.9 (2.4–3.9) <0.001
creatinine (µmol/L) 27 82 (58–121) 28 76 (69–90) 0.49
albumin (g/L) 25 28.6 (24.1–33) 20 40.3 (34.9–41.9) <0.001
CRP (mg/L) 27 74 (18–120) 26 2.4 (1–3.8) <0.001
∆Cq 27 3.71 (3.44–4.09) 28 3.25 (3.02–3.35) <0.001
Normalized Expression of HMGB1 gene 27 0.08 (0.06–0.09) 28 0.11 (0.10–0.13) <0.001
CDI, Clostridioides difficile infection; CRP, C-reactive protein; HMGB1, high-mobility group box 1; n, number of
patients; Q25, lower quartile; Q75, upper quartile; WBC, white blood cells; ∆Cq, difference between the quantification
cycle of the analyzed gene and reference genes. P: p value.
Graphical representation of the data on HMGB1 gene expression is provided in Figure 1.
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Figure 1. Normalized expression of HMGB1 gene in CDI (n = 27) and control (n = 28) groups. Box 
represents 25th and 75th percentile of values with median values marked within the boxes. 
Whiskers represent 5th–95th percentile. CDI, Clostridioides difficile infection; HMGB1, high-
mobility group box 1. 
Next, a possible correlation between HMGB1 gene expression and the selected blood parameters 
was assessed. In the control group, as predicted, no significant correlation was found, whereas in 
the CDI group there was a statistically significant inverse relationship between HMGB1 gene 
expression and CRP level. No other significant relationships were found between the remaining 
parameters (Table 2). 
Table 2. Correlations between HMGB1 gene expression and assessed blood parameters. 
Parameter Correlated with HGMB1 Gene Expression CDI Group Control Group 
Parameters compared r p r p 
WBC −0.29 0.14 −0.16 0.41 
Neutrophils −0.18 0.39 −0.28 0.16 
Creatinine −0.02 0.91 −0.13 0.50 
Albumin 0.40 0.07 0.42 0.07 
CRP −0.42 0.03 −0.09 0.67 
CDI, Clostridioides difficile infection; CRP, C-reactive protein; HMGB1, high-mobility group box 1; p, p value; r, 
correlation coefficient, WBC, white blood cells. 
4. Discussion 
Figure 1. Normalized expression of HMGB1 gene in CDI (n = 27) and control (n = 28) groups.
Box represents 25th and 75th percentile of values with median values marked within the boxes.
Whiskers represent 5th–95th percentile. CDI, Clostridioides difficile infection; HMGB1, high-mobility
grou box 1.
Next, a possible correlation between HMGB1 gene expression and the selected blood parameters
was assessed. In the control group, as predicted, no significant correlation was found, whereas in the
CDI group there was a statistically significant inverse relationship between HMGB1 gene expression and
CRP level. No other significa t relatio ships were found b tween the remaining parameters (Table 2).
Research data are available as supplementary material.
Table 2. Correlations between HMGB1 gene expression and assessed blood parameters.
Parameter Correlated with HGMB1 Gene Expression CDI Group Control Group
Parameters compared r p r p
WBC −0.29 0.14 −0.16 0.41
Neutrophils −0.18 0.39 −0.28 0.16
Creatinine −0.02 0.91 −0.13 0.50
Albumin 0.40 0.07 0.42 0.07
CRP −0.42 0.03 −0.09 0.67
CDI, Clostridioides difficile infection; CRP, C-reactive protein; HMGB1, high-mobility group box 1; p, p value; r,
correlation coefficient, WBC, white blood cells.
4. Discussion
4.1. The Impact of Genetic Factors on the Course of Clostridioides Difficile Infection
Studies assessing the impact of genetic factors on the course of CDI have, so far, been very few.
Garey et al. demonstrated the correlation of region 251 of the IL-8 gene polymorphism with higher
recurrence of CDI, and an increase in fecal IL-8 concentration [17]. Jiang et al. have shown in two
studies that an AA genotype in the 251 position of IL8 is an important predictor of primary CDI [18,19].
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In our previous study, we have shown that the presence of IL-8 +781 T/C polymorphism is associated
with the severity of CDI [20]. IL-8 is key in CDI pathogenesis, promoting chemotaxis of neutrophils
to an infection site, which in turn initiates inflammation of the intestinal mucosa and emergence of
symptoms [2,21]. The interleukin-4 associated single nucleotide polymorphism (SNP) rs2243250 has
been associated with development of CDI in Inflammatory Bowel Disease (IBD) patients [22]. Jose et
al. showed that homozygosity for leptin receptor Q223R SNP significantly increases the risk of
peak peripheral WBC count >20 × 109/L, which is an indicator of adverse outcomes. They have
also demonstrated in a murine model of CDI, that mice homozygous for the same SNP exhibit a
higher leukocyte count in blood and tissue, exaggerated tissue inflammation and higher mortality,
compared with control mice [23].
4.2. The Role of HMGB1 in Clostridioides Difficile Infection
HMGB1 plays an important role in the inflammatory process. It stimulates cell migration to an
inflammation/injury site, which has been demonstrated on neural cells, smooth muscle cells, tumor cells,
monocytes, and neutrophils [24–28]. It also aids in identification of bacterial products, boosting the
innate immune response [29]. Through binding to cellular receptors, such as toll-like receptor 4 (TLR4),
TLR9, and RAGE, HMGB1 activates innate immune cells, endothelial cells to produce proinflammatory
cytokines, chemokines, tissue factor or adhesion molecules [10,29–33]. Furthermore, HMGB1 inhibits
elimination through phagocytosis of apoptotic neutrophils, impeding resolution of inflammation [29].
So far, the role of HMGB1 has been established in inflammatory processes of conditions, such as
arthritis, hepatitis, sepsis, rheumatoid arthritis, and systemic lupus erythematosus [34–36], as well as the
pathogenesis of atherosclerosis and cancer [37,38].
However, studies examining the potential role of HMGB1 in CDI pathogenesis are lacking. It has
been shown in vitro that HMGB1 may be involved in acute inflammation induced by the C. difficile
toxin A. Liu et al. in their study demonstrated that HMGB1 is released from the nucleus into the
cytoplasm and subsequently, extracellularly in response to C. difficile toxin A (TcdA). Pre-treatment
with glycyrrhizin, an HMGB1 inhibitor, delays TcdA-induced cell rounding. Moreover, they have
shown that inducing exogenous rHMGB1 increased MPO activity and intestinal injury in the ‘ileal loop’
surgical model. A statistically significant increase in mRNA expression of several proinflammatory
cytokine genes (TNF-α, IL-1β, IL-6, keratinocyte chemoattractant-KC) in comparison to phosphate
buffered saline (PBS) stimulation has been demonstrated. Interestingly, the effect observed after
introducing rHMGB1 was similar to that of TcdA [39]. In another study the HMGB1 protein was
involved in endoplasmic reticulum stress induced by the TcdA [9]. Gu et al. have shown that treatment
with recombinant C. difficile toxin B (rTcdB) promotes the release of HMGB1 from CT26 cells in a
time-dependent manner. The HMGB1 knockdown CT26 cells treated with rTcdB reduced their ability
to produce IFN-γ, a cytokine important in CDI pathogenesis [40]. Chumbler et al. have shown that
TcdB induces HMGB1 release from the HeLa cell line [41].
4.3. HMGB1 Gene Expression in Different Infections
Apart from the aforementioned study of Efron et al. [12], HMGB1 expression in CDI patients has
been an underexplored subject. Studies delving into the changes in that expression in the course of
different infections have, similarly, been few and far between. There has been an observed reduced
expression of the HMGB1 gene in chronic Hepatitis B virus (HBV) infected patients, which hypothetically
could lead to impaired DNA damage repair and favor development of hepatocellular carcinoma [42].
In contrast to that, an increased expression of the HGMB1 gene was observed in Hepatitis E virus
(HEV) infected patients [15]. In bacterial infections, HMBG1 gene expression was assessed in active
pulmonary tuberculosis, where it was increased in comparison to asymptomatic individuals tested
for latent tuberculosis [43]. In an animal model of sepsis, expression levels of HMGB1 mRNA in the
liver, lungs, kidneys, and small intestine of rats were markedly increased [44]. In another study, Herpes
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simplex type 2 virus (HSV-2) infection reduced HMGB1 expression in HEC-1 cells, derived from human
endometrial cancer, which were used as a model of epithelial cells [45].
As mentioned above, genetic diversity may at least partially explain why the severity of symptoms
varies so drastically in people similar in age and co-morbidities. In our study, the participants with
CDI exhibited clear signs of infection, substantiated by the considerably increased values of WBC and
CRP. HMGB1 is an important factor in the cellular defense response. It could be theorized that the
observed decrease in expression of HMGB1 in CDI patients is a reflection of the system’s diminished
capability to fight the pathogen. That hypothesis is supported by the significant inverse correlation
between HMGB1 expression and CRP demonstrated in our study. The lower the expression of HMGB1,
the higher CRP was found in the blood. However, it remains unclear why the decrease in HMGB1
expression occurs, and whether it is a primary defect making that particular group of people vulnerable
to developing symptoms of CDI or a secondary reaction based on a yet unexplained mechanism in
the course of CDI. Further research into the subject is needed. In our study, we assessed the HMGB1
gene expression in the early phase of infection, which would further support the hypothesis of genetic
predisposition towards CDI. Leaning on in vitro research, the increase in HMGB1 expression in the
course of different infections was fast. In a study by Zhang et al. in an animal model of sepsis,
this increase was detectable in 12 h [44]. Bearing that in mind, should the increase in HMGB1 gene
expression stem from the infection alone, it would be pronounced in our patients, as well. No such
change in our study suggests, again, that it could be a primary defect making that particular group of
people vulnerable to developing symptoms of CDI. Decreased expression of HMGB1 has also been
observed in the course of HBV infection. It is worth noting that no significant changes were observed
comparing acute HBV patients with healthy controls. Generally, only a minority of patients develop
chronic hepatitis B, and, in the study by Mukherjee et al., only in this group was a decrease of HMGB1
gene expression observed. This observation supports the notion that a functioning HMGB1 gene may
be an important element in combating HBV [42].
Fecal HMGB1 was found to be a marker of intestinal inflammation, as it was not only significantly
increased in the stool of Inflammatory Bowel Disease (IBD) patients, compared with controls, but also
indicative of the course of the disease. Moreover, HMGB1 was a very sensitive marker of persistent
local gut inflammation in IBD patients with clinically quiescent disease [46,47]. In our study, we did
not include patients with severe or fulminant CDI, but even in patients with mild or moderate CDI,
a significant increase in CRP was observed, possibly indicating a systemic inflammatory response in
addition to the local inflammation in the colon. Although we did not explore a possible association
between the expression of HMGB1 and polymorphisms in this gene locus in our patients, such a
relationship was theorized by many researchers. Kornblit et al. postulated this relationship based on in
silico modeling, while others demonstrated it in pneumonia and cancer [48–50]. Several polymorphisms
in gene loci of microRNAs regulating HMGB1 expression were also identified [51].
The main limitation of our study was that we did not include patients with severe CDI. Secondly,
we measured the HMGB1 gene expression only at a single time point of infection. Moreover, we cannot
exclude the possibility that CRP level is not a comprehensive marker of systemic inflammation in
our patients due to potential co-morbidities with an inflammatory component, such as autoimmune
diseases, pericarditis, tissue injuries, and other relatively commonly observed conditions. This may
require careful exclusion of such co-morbidities in future study cohorts or inclusion of only those
patients who are at the stage of remission while being recruited for a potential study of a similar scope.
5. Conclusions
We observed a decreased expression of the HMGB1 gene in peripheral blood of patients with mild
or moderate CDI, which hypothetically could reflect their diminished capability to fight the pathogen.
Future investigations should also include patients with severe CDI. It would be beneficial to assess
whether the expression of HMGB1 changes at other time points of infection, especially at the onset and
toward the end of infection.
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Wołkow, P.; Garlicki, A. The presence of IL-8 +781 T/C polymorphism is associated with the parameters of
severe Clostridium difficile infection. Microb. Pathog. 2018, 114, 281–285. [CrossRef]
21. Madan, R.; Petri, W.A., Jr. Immune responses to Clostridium difficile infection. Trends Mol. Med. 2012, 18,
658–666. [CrossRef] [PubMed]
22. Connelly, T.M.; Koltun, W.A.; Sangster, W.; Berg, A.S.; Hegarty, J.P.; Harris, L., III; Deiling, S.; Stewart, D.B.
An interleukin-4 polymorphism is associated with susceptibility to Clostridium difficile infection in patients
with inflammatory bowel disease: Results of a retrospective cohort study. Surgery 2014, 156, 769–775.
[CrossRef] [PubMed]
23. Jose, S.; Abhyankar, M.M.; Mukherjee, A.; Xue, J.; Andersen, H.; Haslam, D.B.; Madan, R. Leptin receptor
Q223R polymorphism influences neutrophil mobilization after Clostridium difficile infection. Mucosal Immunol.
2018, 11, 947–957. [CrossRef] [PubMed]
24. Fages, C.; Nolo, R.; Huttunen, H.J.; Eskelinen, E.; Rauvala, H. Regulation of cell migration by amphoterin.
J. Cell Sci. 2000, 113, 611–620. [PubMed]
25. Degryse, B.; Bonaldi, T.; Scaffidi, P.; Müller, S.; Resnati, M.; Sanvito, F.; Arrigoni, G.; Bianchi, M.E. The high
mobility group (HMG) boxes of the nuclear protein HMG1 induce chemotaxis and cytoskeleton reorganization
in rat smooth muscle cells. J. Cell Biol. 2001, 152, 1197–1206. [CrossRef] [PubMed]
26. Huttunen, H.J.; Fages, C.; Kuja-Panula, J.; Ridley, A.J.; Rauvala, H. Receptor for advanced glycation end
products-binding COOH-terminal motif of amphoterin inhibits invasive migration and metastasis. Cancer Res.
2002, 62, 4805–4811.
27. Rouhiainen, A.; Kuja-Panula, J.; Wilkman, E.; Pakkanen, J.; Stenfors, J.; Tuominen, R.K.; Lepäntalo, M.;
Carpén, O.; Parkkinen, J.; Rauvala, H. Regulation of monocyte migration by amphoterin (HMGB1). Blood
2004, 104, 1174–1182. [CrossRef]
28. Orlova, V.V.; Choi, E.Y.; Xie, C.; Chavakis, E.; Bierhaus, A.; Ihanus, E.; Ballantyne, C.M.; Gahmberg, C.G.;
Bianchi, M.E.; Nawroth, P.P.; et al. A novel pathway of HMGB1-mediated inflammatory cell recruitment that
requires Mac-1-integrin. EMBO J. 2007, 26, 1129–1139. [CrossRef]
29. Zhu, S.; Li, W.; Ward, M.F.; Sama, A.E.; Wang, H. High mobility group box 1 protein as a potential drug
target for infection- and injury-elicited inflammation. Inflamm. Allergy Drug Targets 2010, 9, 60–72. [CrossRef]
30. Yamoah, K.; Brebene, A.; Baliram, R.; Inagaki, K.; Dolios, G.; Arabi, A.; Majeed, R.; Amano, H.; Wang, R.;
Yanagisawa, R.; et al. High-mobility group box proteins modulate tumor necrosis factor-alpha expression
in osteoclastogenesis via a novel deoxyribonucleic acid sequence. Mol. Endocrinol. 2008, 22, 1141–1153.
[CrossRef]
31. Pedrazzi, M.; Patrone, M.; Passalacqua, M.; Ranzato, E.; Colamassaro, D.; Sparatore, B.; Pontremoli, S.;
Melloni, E. Selective proinflammatory activation of astrocytes by high-mobility group box 1 protein signaling.
J. Immunol. 2007, 179, 8525–8532. [CrossRef] [PubMed]
32. Fiuza, C.; Bustin, M.; Talwar, S.; Tropea, M.; Gerstenberger, E.; Shelhamer, J.H.; Suffredini, A.F.
Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells. Blood 2003, 101,
2652–2660. [CrossRef] [PubMed]
33. Lv, B.; Wang, H.; Tang, Y.; Fan, Z.; Chen, F.; Xiao, X. High-mobility group box 1 protein induces tissue factor
expression in vascular endothelial cells via activation of NF-kappaB and Egr-1. Thromb. Haemost. 2009, 102,
352–359. [PubMed]
34. Lotze, M.T.; Tracey, K.J. High-mobility group box 1 protein (HMGB1): Nuclear weapon in the immune
arsenal. Nat. Rev. Immunol. 2005, 5, 331–342. [CrossRef] [PubMed]
35. Wittemann, B.; Neuer, G.; Michels, H.; Truckenbrodt, H.; Bautz, F.A. Autoantibodies to nonhistone
chromosomal proteins HMG-1 and HMG-2 in sera of patients with juvenile rheumatoid arthritis.
Arthritis Rheum. 1990, 33, 1378–1383. [CrossRef]
Microorganisms 2020, 8, 1217 9 of 9
36. Popovic, K.; Ek, M.; Espinosa, A.; Padyukov, L.; Harris, H.E.; Wahren-Herlenius, M.; Nyberg, F.
Increased expression of the novel proinflammatory cytokine high mobility group box chromosomal protein
1 in skin lesions of patients with lupus erythematosus. Arthritis Rheum. 2005, 52, 3639–3645. [CrossRef]
37. Porto, A.; Palumbo, R.; Pieron, M.; Aprigliano, G.; Chiesa, R.; Sanvito, F.; Maseri, A.; Bianchi, M.E.; Porto, A.;
Palumbo, R.; et al. Smooth muscle cells in human atherosclerotic plaques secrete and proliferate in response
to high mobility protein box 1. FASEB J. 2006, 20, E1–E9. [CrossRef]
38. Vakkila, J.; Lotze, M.T. Inflammation and necrosis promote tumor growth. Nat. Rev. Immunol. 2004, 4,
641–648. [CrossRef]
39. Liu, J.; Zhang, B.L.; Sun, C.L.; Wang, J.; Li, S.; Wang, J.F. High mobility group box 1 protein is involved in
acute inflammation induced by Clostridium difficile toxin A. Acta Biochim. Biophys. Sin. 2016, 48, 554–562.
[CrossRef]
40. Gu, H.; Liu, J.; Chen, S.; Qi, H.; Shi, K.; Li, S.; Ma, Y.; Wang, J. High-mobility group box 1 protein contributes
to the immunogenicity of rTcdB-treated CT26 cells. Acta Biochim. Biophys. Sin. 2018, 50, 921–928. [CrossRef]
41. Chumbler, N.M.; Farrow, M.A.; Lapierre, L.A.; Franklin, J.L.; Haslam, D.; Goldenring, J.R.; Lacy, D.B.
Clostridium difficile toxin B causes epithelial cell necrosis through an autoprocessing-independent mechanism.
PLoS Pathog. 2012, 8. [CrossRef]
42. Mukherjee, R.M.; Shravanti, G.V.; Jakkampudi, A.; Kota, R.; Jangala, A.L.; Reddy, P.B.; Rao, P.N.;
Gupta, R.; Reddy, D.N. Reduced expression of DNA damage repair genes High Mobility Group Box1 and
Poly(ADP-ribose) Polymerase1 in inactive carriers of hepatitis B virus infection—A possible stage of viral
integration. J. Clin. Exp. Hepatol. 2013, 3, 89–95. [CrossRef] [PubMed]
43. Lui, G.; Wong, C.K.; Ip, M.; Chu, Y.J.; Yung, I.M.; Cheung, C.S.; Zheng, L.; Lam, J.S.; Wong, K.T.; Sin, W.W.;
et al. HMGB1/RAGE signaling and pro-inflammatory cytokine responses in non-HIV adults with active
pulmonary tuberculosis. PLoS ONE 2016, 11. [CrossRef] [PubMed]
44. Zhang, L.; Yao, Y.; Lu, J.; Yan, X.J.; Yu, Y.; Sheng, Z.Y. Recombinant bactericidal/permeability–increasing
protein inhibits endotoxin-induced High Mobility Group Box1 gene expression in sepsis. Shock 2008, 29,
278–284. [CrossRef] [PubMed]
45. Borde, C.; Barnay-Verdier, S.; Gaillard, C.; Hocini, H.; Maréchal, V.; Gozlan, J. Stepwise release of biologically
active HMGB1 during HSV-2 infection. PLoS ONE 2011, 6. [CrossRef] [PubMed]
46. Vitali, R.; Stronati, L.; Negroni, A.; Di Nardo, G.; Pierdomenico, M.; Del Giudice, E.; Rossi, P.; Cucchiara, S.
Fecal HMGB1 is a novel marker of intestinal mucosal inflammation in pediatric inflammatory bowel disease.
Am. J. Gastroenterol. 2011, 106, 2029–2040. [CrossRef]
47. Palone, F.; Vitali, R.; Cucchiara, S.; Pierdomenico, M.; Negroni, A.; Aloi, M.; Nuti, F.; Felice, C.; Armuzzi, A.;
Stronati, L. Role of HMGB1 as a suitable biomarker of subclinical intestinal inflammation and mucosal
healing in patients with inflammatory bowel disease. Inflamm. Bowel Dis. 2014, 20, 1448–1457. [CrossRef]
48. Kornblit, B.; Munthe-Fog, L.; Petersen, S.L.; Madsen, H.O.; Vindeløv, L.; Garred, P. The genetic variation of
the human HMGB1 gene. Tissue Antigens 2007, 70, 151–156. [CrossRef]
49. Song, W.; Tan, H.; Wang, S.; Zhang, Y.; Ding, Y. Association of High Mobility Group Box Protein B1 gene
polymorphisms with pneumonia susceptibility and severity. Genet. Test. Mol. Biomark. 2019, 23, 3–11.
[CrossRef]
50. Wang, J.; Zhu, J.; Mao, D.H.; Zhu, S.; Mi, X.G.; Yu, Q. An indel polymorphism in the 3’ untranslated region of
HMGB1 confers risk for hepatocellular carcinoma by regulating HMGB1 transcriptional activity in a Chinese
population. Neoplasma 2020, 67, 61–67. [CrossRef]
51. Issac, M.S.M.; Girgis, M.; Haroun, M.; Shalaby, A. Association of genetic polymorphism of pre-microRNA-146a
rs2910164 and serum High-Mobility Group Box 1 with febrile seizures in Egyptian children. J. Child Neurol.
2015, 30, 437–444. [CrossRef] [PubMed]
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
